The MammaTyper® test delivers a precise, quantitative result for each biomarker. Gene expression for each marker is provided as 40-∆∆Cq values.
Based on validated cut-off values (clinical thresholds) each marker is subsequently classified as positive or negative. The combination of the four marker results, accurately determines the subtype according to the St Gallen recommendation.
The quantitative and reproducible 40-ΔΔCq values, which are obtained by using the MammaTyper® test, could be the basis for further differentiation of subtypes beyond today’s routine results — an important factor for individualized treatment in the future.
1 Goldhirsch, A. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann. Oncol. 24, 2206–2223 (2013).